MENLO PARK, Calif. — OrsoBio, a clinical-stage biopharmaceutical company developing treatments for obesity and related metabolic disorders, today announced positive topline results from a Phase 2a proof-of-concept study (NCT06564584) evaluating TLC-2716, the Company’s oral, liver-targeted liver X receptor (LXR) inverse agonist, in patients with severe hypertriglyceridemia (SHTG) and metabolic dysfunction–associated...
Latest News
MADRID, Spain and CAMBRIDGE, Mass. — Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the final results of an observational clinical study aimed at psychometrically characterizing individuals with Phelan-McDermid syndrome (PMS) carrying deletions or pathogenic variants...
MADRID, Spain and CAMBRIDGE, Mass. — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced that the European Medicines Agency (EMA) has authorized its Clinical Trial Application (CTA) to initiate a Phase II study of iadademstat, Oryzon’s potent and...
New York, NY – OS Therapies Inc. (NYSE American: OSTX), the world leader in listeria-based cancer immunotherapies, is honored to celebrate the passage of the Mikaela Naylon Give Kids A Chance Act. Mikaela, like so many other children, courageously battled pediatric cancer – specifically Osteosarcoma. Her legacy through this legislation...
NEW YORK, NY — OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced it was granted an End of Phase 2 Meeting by the United States Food & Drug Administration (“FDA”) to review the OST-HER2 program in the...
New York, NY — OS Therapies Inc. (NYSE American: OSTX)(“OS Therapies” or “the Company”), the world leader in listeria-based cancer immunotherapies, today announced that it has formally initiated a Biologics License Application (BLA) submission to the U.S. Food & Drug Administration (FDA) for OST-HER2 in the prevention or delay of...
New York, NY – OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced statistically significant positive updated interim 2-year overall survival data from the Company’s Phase 2b trial of off-the-shelf immunotherapy candidate OST-HER2 in the prevention of...
New York, NY – OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced positive data in the prevention or delay of amputation during the treatment of primary osteosarcoma for OST-HER2 combined palliative radiation in dogs with unresected...
NEW YORK, NY – OS Therapies Inc. (NYSE American: OSTX), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced statistically significant positive final 2-year overall survival data from the Company’s Phase 2b trial of off-the-shelf immunotherapy candidate OST-HER2 in the prevention or delay of recurrent, fully-resected, pulmonary...
Osaka, Japan – Plasma-activated medium (PAM) shows tumor-fighting effects against the rare form of cancer known as synovial sarcoma, an Osaka Metropolitan University-led research team has found. The group irradiated a mammalian cell culture medium with non-thermal atmospheric-pressure plasma to produce PAM and conducted in vitro tests using human cells and...